Tris Pharma has set its sights on an FDA filing for pipeline drug cebranopadol before the end of this year after the drug achieved significant pain relief in abdominoplasty patients in a late-stage ...
There was an error while loading. Please reload this page.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback